New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc. (HIND) vs Radiopharm Theranostics Limited - Sponsored ADR (RADX)

Vyome Holdings, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are both Biotechnology companies. Vyome Holdings, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are of similar size ($10.6M and $10.2M). Across the 4 metrics below, Vyome Holdings, Inc. leads on 2 and Radiopharm Theranostics Limited - Sponsored ADR on 2.

Valuation

Metric HIND RADX Biotechnology median
P/E n/m — 8.49
P/S 55.90 — 8.56
P/B 1.31 — 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA n/m — 0.69
EV/Sales 12.73 — 8.00
Earnings yield (48.42%) — (35.81%)
Free cash flow yield (52.40%) — (25.41%)

Profitability

Metric HIND RADX Biotechnology median
Gross margin 50.39% — 70.18%
Operating margin (2,851.63%) — 0.00%
Net margin (2,453.92%) — 0.00%
Free cash flow margin (2,928.92%) — 0.00%
Return on equity (71.85%) — (51.58%)
Return on assets (48.02%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric HIND RADX Biotechnology median
Revenue growth (TTM) (55.55%) — 7.20%
EPS growth (last fiscal year) 99.92% (1.97%) 29.04%
Revenue growth, 5-year CAGR (50.98%) — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric HIND RADX Biotechnology median
Debt to equity 0.05 0.00 0.00
Current ratio 3.68 1.16 4.79
Net debt to EBITDA 0.48 0.08 1.01

Dividend

Metric HIND RADX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HIND RADX Biotechnology median
Market cap 10.18m 10.57m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack